Targeted therapy for pediatric low-grade glioma

Pérez, J.; Muchart, Jordi; López, Vicente Santa-María; Capella, Mariona Suñol; Salvador, Noelia; Jaume, Sara Pérez; Martínez, Ofelia Cruz; Madrid, Andrés Morales La

doi:10.1007/s00381-021-05138-3

Cited by 14 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, the identification of BRAF V600E mutations allows targeted disruption by using BRAF inhibitors, with favorable clinical results. 22 The diagnosis of high-grade astrocytoma with piloid features recognizes unusual cases in which a relatively circumscribed tumor with distinct piloid cytology occurs in the setting of a more malignant astrocytoma (WHO grades 3 or 4). 23 These tumors usually occur in adults, exhibit CDKN2A/B deletions, and have a distinct DNA methylation profile that differs from the typical childhood pilocytic astrocytomas.…”

Section: Gliomasmentioning

confidence: 99%

The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know

Osborn

Louis

Poussaint

et al. 2022

AJNR Am J Neuroradiol

119

View full text Add to dashboard Cite

Neuroradiologists play a key role in brain tumor diagnosis and management. Staying current with the latest classification systems and diagnostic markers is important to provide optimal patient care. Publication of the 2016 World Health Organization Classification of Tumors of the Central Nervous System introduced a paradigm shift in the diagnosis of CNS neoplasms. For the first time, both histologic features and genetic alterations were incorporated into the diagnostic framework, classifying and grading brain tumors. The newly published 2021 World Health Organization Classification of Tumors of the Central Nervous System, May 2021, 5th edition, has added even more molecular features and updated pathologic diagnoses. We present, summarize, and illustrate the most salient aspects of the new 5th edition. We have selected the key "must know" topics for practicing neuroradiologists.ABBREVIATIONS: DGONC ¼ diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters; EPN ¼ ependymoma; ETMR ¼ embryonal tumor with multilayered rosettes; FISH ¼ fluorescence in situ hybridization; NEC ¼ not elsewhere classified; NOS = not otherwise specified; MB ¼ medulloblastoma; MGNT ¼ myxoid glioneuronal tumor; MVNT ¼ multinodular and vacuolating neuronal tumor; PF ¼ posterior fossa; SC ¼ spinal cord; ST ¼ supratentorial; WHO ¼ World Health Organization; IDH ¼ isocitrate dehydrogenase

show abstract

Section: Gliomasmentioning

confidence: 99%

The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know

Osborn

Louis

Poussaint

et al. 2022

AJNR Am J Neuroradiol

119

View full text Add to dashboard Cite

show abstract

“…Most pediatric low-grade gliomas, as a further example, are defined by alterations in the mitogen activated protein kinase (MAPK) pathway [22]. The detection of these alterations has led to the development of targeted therapies, directed against these kinases, for example, MEK and BRAF inhibitors [23][24][25]. The efficacy and safety of these agents, for example, dabrafenib or trametinib, are currently being evaluated in clinical trials and may have the potential to replace conventional chemotherapy as a standard of care for pediatric low-grade gliomas [26,27].…”

Section: Treatment Modalities and Related Long-term Issues In Pediatr...mentioning

confidence: 99%

Long-Term Follow-Up of Pediatric CNS Tumor Survivors—A Selection of Relevant Long-Term Issues

2022

View full text Add to dashboard Cite

Introduction: Survivors of pediatric central nervous system (CNS) tumors are at high risk for late effects and long-term morbidity. The quality of survival became increasingly important, as advances in diagnostics, multimodal treatment strategies, and supportive care have led to significant increases in long-term survival. Aim: This review aims to provide a global overview of the potential late effects and long-term follow-up care of CNS tumor survivors, directed to trainees and practitioners with less targeted training in pediatric oncology. Late effects in CNS tumor survivors: A specific focus on CNS tumor survivors relies on cognitive and psychosocial late effects, as they may have an impact on education, professional career, independent living, and quality of life. Further important late effects in CNS tumor survivors include endocrine, metabolic, cardiovascular, and cerebrovascular diseases. Conclusions: Comprehensive long-term follow-up care is essential for pediatric CNS tumor survivors to improve their quality of survival and quality of life. An individualized approach, taking all potential late effects into account, and carried out by an interdisciplinary team, is recommended, and should continue into adulthood. Existing recommendations and guidelines on long-term follow-up care guide the multidisciplinary teams.

show abstract

“…Many of the targeted agents, which have been proven to be effective in early-phase pediatric brain tumor trials (eg, vemurafenib, dabrafenib, bevacizumab, and trametinib), have been licensed for use in adults in many countries. 12 , 13 Even in some MICs where these drugs are available, the high cost continues to be a major hurdle for widespread use of these therapies. Moreover, these drugs need to be given for a long period of time, and the majority of studies have shown the duration of therapy to be over 1 year, which leads to a long-term problem with accessibility and affordability.…”

Section: Drug Access In Lmicsmentioning

confidence: 99%

How Can Genomic Innovations in Pediatric Brain Tumors Transform Outcomes in Low- and Middle-Income Countries?

Bailey

Davidson

Parkes

et al. 2022

JCO Global Oncology

View full text Add to dashboard Cite

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs. org/go/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

show abstract

Targeted therapy for pediatric low-grade glioma

Cited by 14 publications

References 30 publications

The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know

The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know

Long-Term Follow-Up of Pediatric CNS Tumor Survivors—A Selection of Relevant Long-Term Issues

How Can Genomic Innovations in Pediatric Brain Tumors Transform Outcomes in Low- and Middle-Income Countries?

Contact Info

Product

Resources

About